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with COVID-19
To the Editor:
An epidemic cluster of pneumonia cases caused by the novel
coronavirus, SARS-CoV-2, first broke out in Wuhan City, China in
December 2019.1 This infection, named COVID-19, then spread
rapidly throughout continents and was declared pandemic on March
11, 2020. Currently, there are only anecdotal reports of COVID-19 in
immunosuppressedchildren2-4 or inpediatric patientswith cancer, and
so far there is only one Chinese case report5 of pediatric COVID-19
in acute lymphoblastic leukemia (ALL). No case reports describing ALL
onset in patients with COVID-19 have been published. Nonetheless,
few data are available about the possible impact of the drugs currently
being used for COVID-19 on the clinical course of childrenwith ALL.
We hospitalized a 3-year-old boy with fever, epistaxis, and weight
loss. His mother, although asymptomatic, had already tested posi-
tive in a SARS-CoV-2 nasopharyngeal swab. She was tested again
on arrival at hospital and resulted negative. At presentation, the
patient hadmild fever, bruises, hepatosplenomegaly, andmultiple lym-
phadenopathy. He was neither coughing nor in respiratory distress.
Blood tests showed hyperleukocytosis, anemia, and thrombocytope-
nia (white blood cells [WBC] 85.23 × 109/L, hemoglobin 5.7 g/dL and
platelets 19 × 109/L); other results included normal C-reactive pro-
tein, prothrombin time, activated partial thromboplastin time, and uric
acid. A peripheral blood smear showed 80% lymphoid blasts. The chest
X-ray showed a mild diffuse bronchial wall thickening and the chest
computed tomography scan was normal. His nasopharyngeal swab
tested positive for SARS-CoV-2, so he was isolated in a COVID ward
and started receiving antibiotic treatment and intravenous hydration.
From the first day of his hospitalization, the patient started COVID-
19 treatmentwith lopinavir/ritonavir (140/35mgBID) associatedwith
hydroxychloroquine (HCQ; 5 mg/kg BID for the first day and then
2.5mg/kg BID).
The bone marrow smear showed 90% lymphoid blasts FAB L2 on
morphology; immunophenotype was compatible with “common” ALL
(CD123+/CLL1−). The lumbar puncture was negative for blasts.
On day 4, a pruritic confluent maculopapular skin rash (Figure S1)
developed on the trunk and upper arms, then faded spontaneously in
around 24 h. SARS-CoV-2 nasopharyngeal swab testing resulted nega-
tive on days 4 and 6 of COVID-19 treatment.
Following the first negative swab, steroid prephase of AIEOP-
BFM ALL 2017 protocol was started. WBC had already lowered
(26.68 × 109/L) after hydration, blood transfusions, and 48 h after the
start of the combination therapy with HCQ and lopinavir/ritonavir. A
further drastic decrease inWBC (6.6× 109/L) was observed during the
steroid prephase (Figure 1).
The patient was a prednisone good responder on “day 8” of the
steroidprephase (WBC0.93×109/L, lymphoidblasts 6%) and received
his first dose of vincristine-daunorubicin without any relevant adverse
effects. The good response to leukemia treatment was confirmed on
day 15:WBC 0.94 × 109/L with lymphoid blasts 0.4%.
Treating a pediatric patient with a concurrent diagnosis of COVID-
19 and pediatric leukemia was a challenging situation and it was
mandatory to proceed with caution. Since the neoplasm was not
considered to be immediately life threatening, we decided to delay
chemotherapy and prioritize the treatment of the viral infection. Our
concern was that the viral infection could have rapidly worsened if
we had started steroids and chemotherapy on day 1. The slight delay
in the antineoplastic treatment and the concomitant administration
of COVID-19 drugs have not been detrimental to the child’s clinical
course and neither to his initial response to the leukemia treatment.
It can be hypothesized that the presence of the SARS-CoV-2 infec-
tion (known to carry a high burden of systemic inflammation6) could
havepushed thepatient’s leukocyte counthigher in the settingof apre-
existent leukemic clone. However, we observed an interesting effect,
likely HCQ-related, in the significant reduction of the WBC after 48 h
of administration of the drug and before starting the steroid prephase.
In fact, suchWBC reduction is improbably related only to IV hydration
and blood transfusions.
Besides its recognized use in rheumatologic and infectious diseases,
HCQ has been known to have an antineoplastic effect.7 Many ongo-
ing clinical trials are focusing on combining treatment of chloroquine-
HCQ with standard chemotherapies, demonstrating prolonged sur-
vival rates in certain types of cancer.8 However, chloroquine therapy
does not show significant benefits in vivo, possibly due to its inability
to reach effective drug concentrations.7
The use of lopinavir/ritonavir associated with HCQ in COVID-19
pediatric patients was based on local guidelines supported by the
current literature.9-11 Additional evidence supports the potential use
of human immunodeficiency virus protease inhibitors (HIV-PI; eg,
lopinavir) as antineoplastic drugs.12 Furthermore, the preclinical study
of Meier-Stephenson et al13 focused on the identification of HIV-PI-
mediated cytotoxicity in pediatric leukemia cells.
On consulting these reported scientific data, we were confident in
starting the concurrent COVID-19 therapy, taking into consideration
the possible impact on the patient’s leukemic course.
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F IGURE 1 WBC trend in a 3-year-old child with SARS-CoV-2 infection at leukemia onset, and after hydroxychloroquine
(HCQ)+ lopinavir/ritonavir and prednisone (PDN) treatment. Prednisone good response (PGR) on day+8
Our report shows that treatment of childhood acute leukemia in the
setting of a concomitant SARS-CoV-2 infection may be successful. The
timing of chemotherapy and the antiviral treatment must be carefully
weighed on a case-by-case basis. In our patient, a prompt initiation of
anti-COVID-19 drugs and a rapid viral clearance allowed us to start
leukemia treatment with just a slight delay and did not prevent a sat-
isfactory tumor response.
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SUPPORTING INFORMATION
Additional supporting informationmay be found online in the Support-
ing Information section at the end of the article.
